Jump to content

Talk:Gilteritinib

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Clinical trial

[edit]

Results from the ADMIRAL clinical trial : Gilteritinib new standard of care for relapsed, refractory FLT3-mutated acute myeloid leukemia - Rod57 (talk) 14:15, 1 November 2019 (UTC)[reply]

Chemical structure error

[edit]

There is an error in the chemical structure. It should be a diamino-pyrazine in the molecule. See the Oncotarget reference for the correct structure....

Kawase T., Nakazawa T., Eguchi T., Tsuzuki H., Ueno Y., Amano Y., Suzuki T., Mori M., Yoshida T. Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells. Oncotarget. 2019; 10: 6111-6123 --Senior Science (talk) 13:49, 14 October 2020 (UTC)[reply]